Evidence map›Paper›PMID 22553496›Full record

ReviewCold Spring Harbor perspectives in medicine2012

HIV Restriction Factors and Mechanisms of Evasion.

Michael H Malim, Paul D Bieniasz

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 328 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
328citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

328 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. IFN-inducible human phospholipid scramblase 1 (PLSCR1) protein restricts HIV-1 infection by inhibiting membrane fusion.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

268 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael H MalimDepartment of Infectious Diseases, King's College London School of Medicine, Guy's Hospital, London Bridge, London SE1 9RT, United Kingdom. michael.malim@kcl.ac.uk
Paul D Bieniasz

Funding

Vif Antagonism: Lead Discovery and SAR - Project 1P01MH100942 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI STEVENSON, MARIO · 2013 to 2017
$6.0M
Discovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9M
Medical Research Council G0401570Medical Research Council G1000196Medical Research Council G1001081NIAID NIH HHS R37 AI064003NIMH NIH HHS P01 MH100942
6 · The paper itself

Abstract

Retroviruses have long been a fertile model for discovering host-pathogen interactions and their associated biological principles and processes. These advances have not only informed fundamental concepts of viral replication and pathogenesis but have also provided novel insights into host cell biology. This is illustrated by the recent descriptions of host-encoded restriction factors that can serve as effective inhibitors of retroviral replication. Here, we review our understanding of the three restriction factors that have been widely shown to be potent inhibitors of HIV-1: namely, APOBEC3G, TRIM5α, and tetherin. In each case, we discuss how these unrelated proteins were identified, the mechanisms by which they inhibit replication, the means used by HIV-1 to evade their action, and their potential contributions to viral pathogenesis as well as inter- and intraspecies transmission.

Indexed as

Antigens, CDAntiviral Restriction FactorsAPOBEC DeaminasesBone Marrow Stromal Antigen 2Carrier ProteinsCytidine DeaminaseCytosine DeaminaseGenes, vifGPI-Linked ProteinsHIV-1HIV InfectionsHost-Pathogen InteractionsHumansMutationTripartite Motif ProteinsUbiquitin-Protein LigasesAntigens, CDAntiviral Restriction FactorsAPOBEC3 proteins, humanAPOBEC DeaminasesBone Marrow Stromal Antigen 2BST2 protein, humanCarrier ProteinsCytidine DeaminaseCytosine DeaminaseGPI-Linked ProteinsTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesViral Regulatory and Accessory Proteins

Identifiers

PMID22553496
PMCPMC3331687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.